These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 16128675)
21. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Khoshoo V; Armstead C; Landry L Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297 [TBL] [Abstract][Full Text] [Related]
22. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Cappello G; Spezzaferro M; Grossi L; Manzoli L; Marzio L Dig Liver Dis; 2007 Jun; 39(6):530-6. PubMed ID: 17420159 [TBL] [Abstract][Full Text] [Related]
23. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489 [TBL] [Abstract][Full Text] [Related]
24. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Tack JF; Miner PB; Fischer L; Harris MS Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322 [TBL] [Abstract][Full Text] [Related]
26. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440 [TBL] [Abstract][Full Text] [Related]
30. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Reilly MC; Barghout V; McBurney CR; Niecko TE Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674 [TBL] [Abstract][Full Text] [Related]
31. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007 [TBL] [Abstract][Full Text] [Related]
32. Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials. Brenner DM; Lacy BE; Ford AC; Bartolini W; Wu J; Shea EP; Bochenek W; Boinpally R; Almansa C Am J Gastroenterol; 2023 May; 118(5):872-879. PubMed ID: 36227782 [TBL] [Abstract][Full Text] [Related]
33. [Efficacy of newly developed kombucha-based specialized food product for treatment of constipation-predominant irritable bowel syndrome]. Pilipenko VI; Isakov VA; Morozov SV; Vlasova AV; Kochetkova AA Vopr Pitan; 2022; 91(5):95-104. PubMed ID: 36394933 [TBL] [Abstract][Full Text] [Related]
34. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590 [TBL] [Abstract][Full Text] [Related]
35. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan. Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447 [TBL] [Abstract][Full Text] [Related]
36. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Pineton de Chambrun G; Neut C; Chau A; Cazaubiel M; Pelerin F; Justen P; Desreumaux P Dig Liver Dis; 2015 Feb; 47(2):119-24. PubMed ID: 25488056 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]
38. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study. Hawrelak JA; Myers SP J Altern Complement Med; 2010 Oct; 16(10):1065-71. PubMed ID: 20954962 [TBL] [Abstract][Full Text] [Related]
39. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658 [TBL] [Abstract][Full Text] [Related]
40. Nucleotide supplementation: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome [ISRCTN67764449]. Dancey CP; Attree EA; Brown KF Nutr J; 2006 Jun; 5():16. PubMed ID: 16762076 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]